Proactive - Interviews for investors

Orthocell Ltd has submitted an application to the Thailand Food and Drug Administration seeking approval for the sale of its nerve repair product, Remplir™, in the US$84 million Thai market.

This move is part of the company’s broader global expansion strategy, following strong sales growth in Australia, New Zealand, and Singapore.

Thailand has a well-developed healthcare system and a strong medical tourism sector, making it a key market in the Asia-Pacific region.

Orthocell is also evaluating opportunities in Hong Kong, Taiwan, Vietnam, Indonesia, and the Philippines.

The company is awaiting regulatory clearance in the US and Canada, with US FDA 510(k) approval expected in March or April 2025. This would allow Orthocell to commercially distribute Remplir in the US, a market valued at US$1.6 billion.

Approval for the US$75 million Canadian market is anticipated in the second half of the year.

Orthocell aims to capture 20% of the US$3.2 billion available across its selected markets. More than 180 orthopaedic and plastic surgeons currently use Remplir in peripheral nerve repair surgeries in Australia, New Zealand, and Singapore.

#Orthocell, #MedicalTechnology, #NerveRepair, #HealthcareInnovation, #RegulatoryApproval, #Remplir, #Surgery, #CollagenWrap, #MedicalDevices, #Thailand, #AsiaPacific, #MarketExpansion, #USFDA, #Canada, #Orthopaedics, #PlasticSurgery, #Healthcare, #Investment, #Growth, #Revenue

Elixir Energy Ltd has signed two farm-out agreements for its Mongolian natural gas and renewable energy assets.

The agreements transfer a 51% interest in these projects to a UK-registered company controlled by Mongolian business interests, which will cover all costs up to a final investment decision (FID) for gas or renewable development.

The first farm-out agreement involves Elixir’s Mongolian coal bed methane (CBM) assets, including the Nomgon CBM production sharing contract (PSC) and related equipment and facilities.

The second agreement applies to the company’s renewable energy business, covering the Solar Ilch pre-development solar farm, wind and solar monitoring equipment, and associated intellectual property.

Elixir stated that these agreements will allow the company to focus on its Grandis Gas Project in Queensland, with the potential to fully exit the Mongolian projects under pre-agreed terms.

The total possible payments from the agreements could reach A$56 million. Both deals include conditional put and call options, with exit valuations linked to booked reserves and installed renewable capacity.

#ElixirEnergy, #NaturalGas, #RenewableEnergy, #Mongolia, #Queensland, #EnergyInvestment, #FarmOut, #GasExploration, #SolarEnergy, #WindEnergy, #CoalBedMethane, #JointVenture, #GrandisProject, #EnergyDevelopment, #InvestmentDeals, #OilAndGas, #Australia, #EnergyTransition, #BusinessNews, #GasReserves

Lightning Minerals Ltd (ASX:L1M) CEO Alex Biggs talked with Proactive about the company’s latest drilling activities at the Esperança lithium project in Brazil.

Biggs shared that drilling has commenced after six months of preparation across three tenements in Brazil’s Lithium Valley.

The Esperança project has confirmed spodumene-bearing pegmatite, indicating lithium presence.

The drilling program will cover 2,000 metres across 14 holes, with the flexibility to adapt as necessary.

Biggs noted that the campaign is expected to take around eight weeks, with assay results anticipated within four to six weeks.

He mentioned that Lightning Minerals will provide market updates as drilling progresses and may fast-track assays depending on early results.

Beyond Esperança, Lightning Minerals is also focused on its Caraíbas and Canabrava projects.

Biggs highlighted strong lithium values from soil sampling and reiterated the company’s commitment to further exploration in Brazil, which he described as a cost-effective and highly prospective lithium region.

For more updates on Lightning Minerals and other mining insights, visit Proactive’s YouTube channel.

#LightningMinerals #LithiumExploration #ASXNews #MiningNews #EsperançaProject #BrazilLithium #BatteryMetals #MiningUpdates #ProactiveInvestors #ElectricVehicles

Power Nickel Inc CEO Terry Lynch joined Steve Darling from Proactive to announce the company’s rebranding to Power Metallic Mines Inc., effective February 21st, 2025. The company will continue to trade under the ticker symbol PNPN on the TSX Venture Exchange and PNPNF on the OTCQB.

Lynch explained that the name change reflects a strategic shift as the company’s deposit has evolved from primarily nickel to a polymetallic opportunity, with potential reserves of copper, noble metals (PGEs, gold, silver), and nickel in equal parts.

Additionally, the company has upsized its private placement offering by $10 million, increasing the total proceeds to $50 million. This financing, the company’s first brokered financing, is led by major institutions including BMO and Hannam UK and was upsized due to high investor demand, strengthening institutional support.

Power Metallic Mines was also recognized as one of the 2024 TSX Venture 50 top performers, ranking as the top mining company and fourth overall with an impressive 365% share price appreciation in 2024. The TSX Venture 50 companies delivered an average share price appreciation of 207% and collectively hold a market capitalization of $21.7 billion, up by $16 billion year-over-year.

Lynch noted that last year’s exploration confirmed the Lion Zone as a standout asset, and 2025 is expected to be a pivotal year as the company, now fully funded, plans to double its exploration programs.

#proactiveinvestors #powernickelinc #tsxv #pnpn #otcqb #cmetf #nickel #mining #invest #investing #PowerMetallicMines #MiningIndustry #PolymetallicExploration #Copper #Nickel #TSXVenture #TerryLynch #ProactiveInvestors #InstitutionalInvestment #Gold #Silver #PGMs #Investing #ResourceSector #MiningNews

West Wits Mining Ltd (ASX:WWI) chairman Michael Quinert spoke with Proactive’s Tylah Tully about securing a credit approval term sheet for a senior debt syndicated loan facility of up to ZAR 902.5 million (about US$50 million).

He highlighted that this funding, backed by two of South Africa’s leading financial institutions, was a critical step forward for the company.

The funds will support the Qala Shallows Gold Project, part of the larger Witwatersrand Basin Project.

Quinert noted that Qala Shallows had a five-million-ounce resource, with initial production targeting one million ounces over a 17.9-year mine life.

“This has been the challenge for the last 12 to 18 months — can we secure institutional-grade backing for this project? Now that we have, it gives us a strong platform to move forward,” Quinert said.

With the senior debt facility secured, West Wits Mining now focuses on finalising the remaining equity funding component.

Quinert remains optimistic, citing the strong gold price environment and the validation from institutional lenders as key drivers for the company’s next steps.

#WestWitsMining #ASXWWI #GoldMining #MiningNews #QalaShallows #GoldStocks #Investing #Witwatersrand #Funding #ProactiveInvestors

ACG Metals chairman and CEO Artem Volynets talked with Proactive's Stephen Gunnion about the company's strategic focus for 2025, including the construction of the sulphide expansion project at its Gediktepe mine. Volynets confirmed that the project is on track for commissioning in early 2026, setting ACG Metals on the path to becoming a copper producer with an anticipated output of up to 25,000 tonnes of copper equivalent annually.

In the interview, Volynets highlighted the transformational year ACG Metals had in 2024, transitioning from a SPAC to a fully operational company through the acquisition of the Gediktepe asset. The company raised $200 million in debt to finance the expansion and restructure acquisition debt, demonstrating strong financial progress. "Now with the acquisition complete, the project fully funded, and staffed with a very experienced team, we are moving to execute on the base case scenario," Volynets said.

ACG Metals achieved $75 million in EBITDA last year, and with the sulphide expansion, the base case scenario projects EBITDA to exceed $100 million. As the company shifts from gold and silver doré production to a focus on copper, it aims to see a rerating of its shares by four to five times, aligning with industry peers.

For more insightful interviews and updates, visit Proactive's YouTube channel. Don't forget to like this video, subscribe to the channel, and turn on notifications for the latest content.

#ACGMetals #CopperProduction #ArtemVolynets #MiningIndustry #SulphideExpansion #GediktepeAsset #GoldToCopper #ProactiveInterviews #MiningNews #EBITDAGrowth

Ananda Pharma Plc finance director Jeremy Sturgess-Smith talked with Proactive's Stephen Gunnion about the company's progress with MRX1, a promising treatment for chemotherapy-induced peripheral neuropathy (CIPN) and endometriosis pain. Ananda has completed the final GMP-certified batch needed for regulatory approval, marking a significant milestone in its clinical journey.

Sturgess-Smith explained, "What we've done is we've now completed all the preparatory work before we can manufacture MRX1 to deliver to patients," emphasising the upcoming trials in Edinburgh and Australia. The trials include CIPN and endometriosis studies at Edinburgh University, as well as a phase one pharmacokinetic (PK) study in Australia.

The next steps involve ethics submissions and discussions with the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) to ensure compliance with regulatory standards. Approval from independent ethics panels will ensure the clinical trials meet ethical standards, while stability data from these trials will support potential licensing with global regulators, including the FDA in the US and the EMA in Europe.

Stay tuned to Proactive's YouTube channel for more updates on Ananda Pharma's clinical progress. Don't forget to like this video, subscribe to our channel, and enable notifications for the latest insights!

#AnandaPharma #MRX1 #ClinicalTrials #CIPN #Endometriosis #PharmaNews #Biotech #MHRA #FDA #Pharmacokinetics #ProactiveInvestors

SEEEN plc (AIM:SEEN) CEO Adrian Hargrave talked with Proactive's Stephen Gunnion about the company’s impressive growth trajectory and its focus for 2025. SEEEN, a video technology platform business, reported a revenue increase from $2.1 million in 2023 to $3.2 million in 2024, with an annualised run rate of $5 million. Hargrave highlighted the company's dual approach, blending high-margin technology solutions with consultancy services for YouTube channels and creators.

The company’s AI-driven platform helps clients monetise video content by identifying engaging segments and facilitating sales through contextual calls to action. SEEEN is gaining traction in the sports, e-commerce, and education sectors, showcasing innovative tools like video commerce and targeted training solutions.

In 2025, SEEEN aims to maintain its cash flow-positive status while driving sales across its core vertical markets, including sports, retail, and social media. The company also plans to enhance its training solutions, a new growth avenue developed with American Leak Detection.

For more insightful interviews, visit Proactive's YouTube channel. Don’t forget to like this video, subscribe, and enable notifications for the latest updates!

#SEEENplc #AdrianHargrave #VideoCommerce #AItechnology #ContentMonetization #SportsTech #Ecommerce #EdTech #2025Growth #ProactiveInvestors

Georgina Energy PLC (LSE:GEX) CEO Anthony Hamilton talked with Proactive's Stephen Gunnion about the company's latest progress, including the near-completion of the purchase of the Mt Winter permit in Northern Territory. Hamilton highlighted that acquiring 100% control of the project offers Georgina Energy complete autonomy over its operations, eliminating external influences.

He explained, "We've ended up with 100% control, 100% control of our destiny, and the program that we want to undertake isn't subject to anybody else's influence." This transition from a joint venture to full ownership allows the company to streamline its strategic objectives, particularly regarding the EPA155 permit.

Hamilton detailed the process following the share sale agreement execution, including awaiting the Aboriginal Land Rights Agreement (ALRA) and the subsequent ministerial approval. Once granted, Georgina Energy will proceed with its drilling approval application alongside a comprehensive resource revaluation.

The discussion also touched on the company’s Western Australia Officer Basin operations, where severe weather, including a major cyclone, has delayed the Environmental Impact Study (EIS). Despite these challenges, Georgina Energy remains focused on maintaining its 60-day EIS completion target.

Stay tuned to Proactive's YouTube channel for more insightful interviews. Don’t forget to give this video a like, subscribe to our channel, and enable notifications for future updates!

#GeorginaEnergy #AnthonyHamilton #MtWinterPermit #OilAndGas #NorthernTerritory #WesternAustralia #ResourceExploration #ShareholderValue #EnergySector #ProactiveInvestors

Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt takes Proactive's Stephen Gunnion through the latest findings on IMU-856, a drug candidate initially studied for celiac disease. New data suggests that IMU-856 significantly increases endogenous GLP-1 levels in a dose-dependent manner, which could make it a potential oral treatment for obesity.

Vitt detailed the results of a post hoc analysis from a Phase 1b clinical trial, where patients receiving the highest dose of IMU-856 experienced a 250% increase in baseline GLP-1 levels. He also discussed preclinical safety studies in rats, which demonstrated a dose-dependent reduction in weight gain—further supporting the drug's potential in obesity management.

The global obesity treatment market is projected to reach $170 billion, with current solutions mainly relying on injectable GLP-1 mimetics. Vitt highlighted that IMU-856’s potential as an oral therapy could offer a new and more convenient option for patients.

Stay updated on Immunic Inc’s progress by watching Proactive’s latest interviews. Don’t forget to like this video, subscribe to our channel, and enable notifications for more updates.

#ImmunicInc #IMUX #Biotech #Pharmaceuticals #GLP1 #ObesityTreatment #ClinicalTrials #Healthcare #Investing #ProactiveInvestors